Vitruvias Therapeutics Thyroid Tablet Recall Controversy Explained

Vitruvias Therapeutics issued a nationwide recall of one lot of its prescription Thyroid Tablets, USP 30 mg in August 2026 after testing found that the medication could be more potent than intended. The recalled tablets contain the thyroid hormones levothyroxine and liothyronine and are prescribed to treat hypothyroidism. Excessive thyroid hormone can cause hyperthyroidism and potentially serious cardiovascular effects, with elderly patients, pregnant women and infants identified as particularly vulnerable. Vitruvias says it has not received any reports of adverse events known to be associated with the recalled lot. The recall applies to one specific lot—not all Vitruvias thyroid medication—and the company and FDA advise patients not to abruptly stop taking the drug without first consulting a healthcare provider.

Vitruvias Therapeutics Thyroid Tablet Recall

Vitruvias Recalled One Lot Of Thyroid Tablets Nationwide. Vitruvias Therapeutics announced on August 21, 2026 that it was voluntarily recalling Lot 504950 of Thyroid Tablets, USP 30 mg to the consumer level. The FDA publicly posted the company recall announcement on August 24. [FDA]

Testing Found The Tablets Could Be Superpotent. According to Vitruvias and the FDA notice, testing confirmed the potential for tablets in the affected lot to be “superpotent,” meaning patients could receive more thyroid hormone than intended from the medication. The public recall announcement does not disclose the precise test results, how far above specification the medication tested or when the potency problem was first discovered. [FDA]

The Recall Is Nationwide. Vitruvias distributed the affected lot to its direct accounts across the United States. Distribution began January 31, 2025 and continued through September 30, 2025. [FDA] [USA Today]

Which Thyroid Tablets Are Recalled?

The Recall Is Limited To Vitruvias Thyroid Tablets USP 30 mg, Lot 504950. The affected prescription medication can be identified by the following information:

Product: Thyroid Tablets, USP 30 mg

NDC: 69680-166-00

Lot: 504950

Expiration date: September 30, 2026

[FDA]

The Recall Does Not Apply To Every Vitruvias Thyroid Tablet. The company’s announcement identifies only Lot 504950 of the 30 mg strength. Other Vitruvias strengths and lots were not included in the August 2026 recall announcement. [FDA]

Thousands Of Units Were Released

Vitruvias Released 3,655 Units From The Affected Lot. The FDA-posted recall notice says 3,655 units of Lot 504950 were released. [FDA]

The Company Says 1,955 Units Were Sold. Vitruvias reported that 1,955 of the released units had been sold. The company distributed the affected product between January and September 2025, meaning the recall was announced nearly a year after the final listed distribution date and approximately five weeks before the lot’s September 30, 2026 expiration date. The recall announcement does not explain why the potency issue was detected at that point in the product’s life cycle. [FDA] [Pharma Now]

What Is In Vitruvias Thyroid Tablets?

The Medication Contains Two Thyroid Hormones. Vitruvias Thyroid Tablets USP are a natural thyroid preparation derived from porcine thyroid glands. They contain both levothyroxine, known as T4, and liothyronine, known as T3. [FDA] [DailyMed]

Each 30 mg Tablet Is Labeled As Containing 19 mcg Of Levothyroxine And 4.5 mcg Of Liothyronine. The FDA’s DailyMed labeling for NDC 69680-166-00 identifies the 30 mg tablet as a half-grain thyroid tablet containing those labeled amounts of T4 and T3. [DailyMed]

The Drug Is Used To Treat An Underactive Thyroid. Hypothyroidism occurs when the thyroid does not produce enough thyroid hormone. Thyroid-replacement medications supply hormones that the body is missing, making accurate potency particularly important because too little or too much hormone can produce medical problems. [FDA]

Risks From Superpotent Thyroid Medication

Too Much Thyroid Hormone Can Cause Hyperthyroidism. The company’s FDA-posted risk statement says taking superpotent thyroid medication can cause symptoms of an overactive thyroid, including weight loss, heat intolerance, fatigue, nervousness and muscle weakness. [FDA MedWatch]

Potential Cardiovascular Effects Include High Blood Pressure, Chest Pain And Abnormal Heart Rhythms. The recall notice specifically warns about hypertension, chest pain, rapid heart rate and heart-rhythm disturbances. [FDA]

Elderly Patients Face Particular Cardiac Risks. Vitruvias warned that excessive thyroid hormone levels among elderly patients have been associated with adverse outcomes, particularly involving cardiovascular health. [FDA]

Risks During Pregnancy

Pregnant Patients Are Among The Groups Identified As Being At Higher Risk. Maintaining appropriate thyroid hormone levels during pregnancy is medically important, and the company’s recall statement warns that overtreatment of hypothyroidism has been associated with higher rates of maternal and fetal complications. [FDA MedWatch]

Potential Pregnancy Complications Include Premature Delivery And Low Birth Weight. Those outcomes are specifically identified in the FDA-posted recall notice as possible concerns associated with overtreatment during pregnancy. [FDA]

Risks For Infants

Infants Are Also Identified As A Higher-Risk Population. Vitruvias said prolonged exposure to excessive thyroid hormone may negatively affect growth and development in infants. [FDA]

No Reported Adverse Events So Far

Vitruvias Says It Has Received No Reports Of Adverse Events Known To Be Associated With The Recall. The company stated that, as of its August 21 announcement, it had not received reports of adverse events known to be related to Lot 504950. [FDA] [FDA MedWatch]

The Recall Was Initiated Because Of Testing Rather Than Reported Patient Injuries. Based on the public announcement, the trigger for the recall was a potency-testing result rather than a cluster of reported illnesses or injuries. That distinction is important: the product poses a potential safety risk, but no confirmed patient injury related to this particular recall had been announced as of August 25, 2026. [FDA]

Vitruvias Response

Vitruvias Is Contacting Wholesalers. The company said it was proactively contacting wholesalers by email and telephone and directing them to discontinue distribution of the recalled lot. [FDA]

The Company Is Arranging For The Recalled Product To Be Destroyed. Vitruvias said it was making arrangements for destruction of recalled medication remaining in the distribution chain. [FDA]

The Recall Is Being Conducted With The FDA’s Knowledge. The FDA notice describes the action as a voluntary recall initiated by Vitruvias Therapeutics and conducted with the knowledge of the federal regulator. The FDA’s posting of a company recall announcement does not mean the agency endorses the company or its product. [FDA]

What Patients Are Being Told To Do

Patients Are Specifically Told Not To Abruptly Stop Taking The Recalled Medication On Their Own. The company and FDA say patients who are currently taking tablets from Lot 504950 should contact their healthcare provider for guidance or a replacement prescription rather than simply discontinuing thyroid treatment. [FDA MedWatch]

Patients Experiencing Possible Problems Are Told To Contact A Healthcare Provider. The FDA notice advises consumers who experience problems potentially connected to the medication to contact their physician or other healthcare professional. [FDA]

Suspected Adverse Events Can Be Reported Through FDA MedWatch. Healthcare professionals and patients can report suspected drug reactions and quality problems to the FDA’s MedWatch adverse-event reporting system. [FDA MedWatch]

Why Potency Problems Matter With Thyroid Medication

The Purpose Of Thyroid-Replacement Therapy Is To Maintain Appropriate Hormone Levels. A medication that contains more active thyroid hormone than its label indicates can push a patient receiving replacement therapy toward an excessive hormone level, potentially producing symptoms of hyperthyroidism. [FDA]

Superpotency Has Prompted Thyroid-Drug Recalls Before. In 2020, Acella Pharmaceuticals recalled certain lots of NP Thyroid after testing found some tablets could contain as much as 115% of the labeled amount of liothyronine. That was a separate product and company, but it illustrates why regulators and manufacturers treat thyroid-drug potency deviations as a potential safety issue. [FDA]

What Is And Is Not Known About The Vitruvias Recall

The Public Recall Notice Does Not Say How Superpotent The Tablets Were. Neither the FDA-posted announcement nor its MedWatch bulletin provides a percentage showing how much levothyroxine or liothyronine was detected compared with the labeled amount. [FDA]

The Notice Does Not Explain The Cause Of The Potency Problem. The available announcement does not identify a manufacturing error, formulation problem, storage issue or other root cause for the test result. No publicly announced finding establishes how the affected lot became potentially superpotent. [FDA]

There Is No Public Finding Of Intentional Misconduct. The current issue is a drug-quality recall, not a public accusation that Vitruvias intentionally sold overly potent medication. The company voluntarily initiated the recall after testing and is working with wholesalers to remove the affected product. [FDA]

Current Status

The Recall Remains Focused On One Specific Lot. As of August 25, 2026, the FDA recall database identifies Vitruvias Thyroid Tablets USP 30 mg, Lot 504950, as the product involved in the nationwide recall. There has been no public expansion of the recall to all Vitruvias thyroid tablets. [FDA Recalls]

No Recall-Related Adverse Events Have Been Announced. Vitruvias continues to state that it has not received reports of adverse events known to be related to the recalled lot. [FDA MedWatch]

Several Questions Remain Unanswered. The company’s public notice does not state the magnitude of the potency deviation, the cause of the problem or why testing identified the issue after distribution of the lot had ended. Those details could become important if the FDA or Vitruvias releases additional information about the recall.